Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery
Primary Purpose
Nociceptive Pain, Goal-directed Therapy, Hemodynamic Instability
Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Nol-Index guided analgesia
Standard Analgesia
Sponsored by
About this trial
This is an interventional treatment trial for Nociceptive Pain
Eligibility Criteria
Inclusion Criteria:
- moderate-to-high risk cardiac or vascular surgery
- ASA 2-4
Exclusion Criteria:
- chronic arrhythmia (e.g. atrial fibrillation)
- aortic insufficiency
- pacemaker
- implanted defibrillator
- valve surgery
Sites / Locations
- Anesthesia Department, Erasme Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Nol-Guided Analgesia Group
Standard Analgesia Group
Arm Description
In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
Outcomes
Primary Outcome Measures
Remifentanil requirement
µg/kg/hour required during general anesthesia
Secondary Outcome Measures
Norepinephrine requirement
µg/kg/hour required during general anesthesia
propofol requirement
mg/kg/hour required during general anesthesia
nicardipine requirement
mg/kg/hour required during general anesthesia
esmolol requirement
mg/kg/hour required during general anesthesia
Intraoperative hemodynamic instability
Occurence of hypotension, hypertension, bradycardia or tachycardia
Number of patients with 28 day composite and individual adverse outcomes
renal failure, cardiac ischemia, ileus, stroke, new onset arrhythmia, etc
Heart Rate
Heart rate during anesthesia
Systolic Blood Pressure
systolic blood pressure during anesthesia
Diastolic Blood Pressure
diastolic blood pressure during anesthesia
Mean Blood Pressure
mean blood pressure during anesthesia
Cardiac Output
cardiac output during anesthesia
Full Information
NCT ID
NCT04137991
First Posted
October 8, 2019
Last Updated
June 30, 2022
Sponsor
Erasme University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04137991
Brief Title
Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery
Official Title
Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
October 10, 2019 (Actual)
Primary Completion Date
November 1, 2021 (Actual)
Study Completion Date
November 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Erasme University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study will investigate the potential of guiding remifentanil analgesia during cardiac and vascular surgery in moderate to high risk patients requiring general anesthesia.
Detailed Description
Justification:
Moderate-to-high risk cardiovascular surgery is associated with perioperative morbidity and mortality. These patients undergo general anesthesia and often require tight blood pressure control (e.g., using norepinephrine titration) to avoid the complications associated with hypotension and reduced cardiac output. Standard analgesia opioid titration to control nociception (i.e., the patient's unconscious response to noxious stimuli) is based on the anesthesiologist's experience and variations in the patient's heart rate and blood pressure. This causes anesthesiologists to often give too much analgesic, which can lead to inhibition of the sympathetic autonomic nervous system, hypotension, and associated side effects. A recently developed nociception monitor, the PMD-200 (Medasense, Israel), is capable of measuring the patient's level of nociception-antinociception balance and can guide opioid administration. This monitor may allow anesthesiologists to administer only the required amount of opioid, which may lead to better hemodynamic stability and better postoperative outcome.
Objectives:
The goal of this study is to determine if titrating analgesia using the Nol-Index, when compared to standard care, leads to decreased infused remifentanil, decreased norepinephrine, increased cardiac output, more stable blood pressure control, and decreased postoperative complications in moderate-to-high risk patients undergoing cardiac or vascular surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nociceptive Pain, Goal-directed Therapy, Hemodynamic Instability, Nol-Index, Remifentanil, Cardiac Surgery, Vascular Surgery, General Anesthesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nol-Guided Analgesia Group
Arm Type
Experimental
Arm Description
In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
Arm Title
Standard Analgesia Group
Arm Type
Active Comparator
Arm Description
Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
Intervention Type
Device
Intervention Name(s)
Nol-Index guided analgesia
Intervention Description
Monitor that indicates the level of nociception-antinociception balance
Intervention Type
Other
Intervention Name(s)
Standard Analgesia
Intervention Description
Administration of remifentanil based guided by heart rate, blood pressure, and experience
Primary Outcome Measure Information:
Title
Remifentanil requirement
Description
µg/kg/hour required during general anesthesia
Time Frame
2 to 8 hours
Secondary Outcome Measure Information:
Title
Norepinephrine requirement
Description
µg/kg/hour required during general anesthesia
Time Frame
2 to 8 hours
Title
propofol requirement
Description
mg/kg/hour required during general anesthesia
Time Frame
2 to 8 hours
Title
nicardipine requirement
Description
mg/kg/hour required during general anesthesia
Time Frame
2 to 8 hours
Title
esmolol requirement
Description
mg/kg/hour required during general anesthesia
Time Frame
2 to 8 hours
Title
Intraoperative hemodynamic instability
Description
Occurence of hypotension, hypertension, bradycardia or tachycardia
Time Frame
2 to 8 hours
Title
Number of patients with 28 day composite and individual adverse outcomes
Description
renal failure, cardiac ischemia, ileus, stroke, new onset arrhythmia, etc
Time Frame
28 days
Title
Heart Rate
Description
Heart rate during anesthesia
Time Frame
2 to 8 hours
Title
Systolic Blood Pressure
Description
systolic blood pressure during anesthesia
Time Frame
2 to 8 hours
Title
Diastolic Blood Pressure
Description
diastolic blood pressure during anesthesia
Time Frame
2 to 8 hours
Title
Mean Blood Pressure
Description
mean blood pressure during anesthesia
Time Frame
2 to 8 hours
Title
Cardiac Output
Description
cardiac output during anesthesia
Time Frame
2 to 8 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
moderate-to-high risk cardiac or vascular surgery
ASA 2-4
Exclusion Criteria:
chronic arrhythmia (e.g. atrial fibrillation)
aortic insufficiency
pacemaker
implanted defibrillator
valve surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luc Barvais, MD, PhD
Organizational Affiliation
Erasme University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Anesthesia Department, Erasme Hospital
City
Brussels
Country
Belgium
12. IPD Sharing Statement
Learn more about this trial
Nol-Index Guided Remifentanil Analgesia Versus Standard Analgesia During Moderate-to-High Risk Cardiovascular Surgery
We'll reach out to this number within 24 hrs